3M Discontinues Collaboration with Gen-Probe to Develop Molecular Tests for Healthcare-Associated ...(rom estimates orprojections contained in...)

Date:6/16/2008

rom estimates or projections contained in the forward-looking statements include but are not limited to, the risk that: (i) the companies will not be able to reach agreement on a new relationship, (ii) Gen-Probe's assays for HCAIs will not be successfully developed or integrated onto its next-generation instrument platforms, (iii) Gen-Probe may decide not to proceed with development of assays for HCAIs, (iv) new products, such as assays to detect HCAIs or new instruments, will not be cleared for marketing in the timeframes Gen-Probe expects, if at all, (v) the market for the sale of new products may not develop as expected, (vi) Gen-Probe may not be able to compete effectively, (vii) Gen-Probe may not be able to maintain its current corporate collaborations and (viii) competitors may challenge Gen-Probe's intellectual property rights. The foregoing describes some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see the documents that 3M and Gen-Probe file with the SEC, including the most recent annual reports on Form 10-K and all subsequent periodic reports. Neither 3M nor Gen-Probe assume any obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

Contact:

Gen-Probe 3M

Michael Watts Stephanie Sanderson

Senior director, investor relations and 3M Public Relations

corporate communications 651-733-8588

858-410-8673

'/>"/>

SOURCE Gen-Probe Incorporated Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
2. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
3. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
4. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
5. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
6. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
7. SGX Provides Update on BCR-ABL Collaboration
8. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
9. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
10. Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement
11. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease